The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Chulkova S.V.

N.N. Blokhin National Medical Research Center of Oncology;
Pirogov Russian National Research Medical University

Sholokhova E.N.

N.N. Blokhin National Medical Research Center of Oncology

Poddubnaya I.V.

Russian Medical Academy of Continuous Professional Education

Gladilina I.A.

N.N. Blokhin National Medical Research Center of Oncology;
Pirogov Russian National Research Medical University

Egorova A.V.

Pirogov Russian National Research Medical University

Stilidi I.S.

N.N. Blokhin National Medical Research Center of Oncology;
Pirogov Russian National Research Medical University

Expression of transferrin receptor 1 and β1-integrins correlates with estrogen receptor status and immune infiltration in breast cancer

Authors:

Chulkova S.V., Sholokhova E.N., Poddubnaya I.V., Gladilina I.A., Egorova A.V., Stilidi I.S.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2024;86(4): 23‑30

DOI: 10.17116/patol20248604123

Views: 653

Downloaded: 0

Buy for 300₽
Contact the author
Table of contents

EXPRESSION OF TRANSFERRIN RECEPTOR 1 AND Β1-INTEGRINS CORRELATES WITH ESTROGEN RECEPTOR STATUS AND IMMUNE INFILTRATION IN BREAST CANCER
EXPRESSION OF TRANSFERRIN RECEPTOR 1 AND Β1-INTEGRINS CORRELATES WITH ESTROGEN RECEPTOR STATUS AND IMMUNE INFILTRATION IN BREAST CANCER

To cite this article:

Chulkova SV, Sholokhova EN, Poddubnaya IV, Gladilina IA, Egorova AV, Stilidi IS. Expression of transferrin receptor 1 and β1-integrins correlates with estrogen receptor status and immune infiltration in breast cancer. Russian Journal of Archive of Pathology. 2024;86(4):23‑30. (In Russ.)
https://doi.org/10.17116/patol20248604123

 
Подписка 2025-2 (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Close metadata
Recommended articles:
Complications after one-stage and two-stage breast reco­nstruction depe­nding on the method of reco­nstruction and risk factors. Plastic Surgery and Aesthetic Medi­cine. 2024;(2):16-21
Perforator fasciocutaneous flaps in rese­ctions for breast cancer. Plastic Surgery and Aesthetic Medi­cine. 2024;(2):81-86
The impact of arti­ficial inte­lligence on double reading of mammograms. Russian Journal of Preventive Medi­cine. 2024;(5):32-37
Reco­nstructive plastic surgery in combined treatment of breast cancer: predictive risk factors of complications and reco­nstruction failure. P.A. Herzen Journal of Onco­logy. 2024;(3):13-19
Targeted lymphadenectomy with sentinel lymph node biopsy in patients with breast cancer cT1-3N1M0 after neoadjuvant poly­chemotherapy. P.A. Herzen Journal of Onco­logy. 2024;(3):73-78
Breast cancer: types of implantable mate­rials for replacement of postresection defe­cts. P.A. Herzen Journal of Onco­logy. 2024;(3):85-89
Intrathecal chemotherapy for leptomeningeal meta­stases in patients with breast cancer. Burdenko's Journal of Neurosurgery. 2024;(3):31-37
Indo­cyanine green is an inte­gral part of breast reco­nstructive surgery using perforator flaps. Piro­gov Russian Journal of Surgery. 2024;(8):34-40
Leading trends in breast cancer inci­dence in the Repu­blic of Crimea. P.A. Herzen Journal of Onco­logy. 2024;(4):42-47

Cancer cells can aberrantly express various markers, including transferrin receptor 1 (CD71) and β1-integrin molecules. Their role in invasion, migration and metastasis has been demonstrated. Determination of their expression in breast cancer (BC) may be an important point to characterize the clinical course of the tumor and prognosis of the disease.

OBJECTIVE

To study of transferrin receptor 1 (CD71) expression by primary breast cancer cells in correlation with tumor cell phenotype.

MATERIAL AND METHODS

Determination of BC phenotype: immunohistochemical staining method (immunofluorescence). Antibodies to ER (estrogen receptors), KL-1 (pancytokeratin), CD71 (transferrin receptor), CD29 (β1-integrins). CD45, CD3, CD4, CD8, CD20 infiltration was also evaluated. ZEISS microscope (AXIOSKOP; Germany), method of G.J. Hammerling et al. Statistical processing: IBM-SPSS Statistics v.21.

RESULTS

63% of BC cases had CD71+ phenotype. CD71-mosaic tumors were observed in 14.4%. β1-integrin expression was monomorphic in 51.6% of cases and mosaic in 38.7%. 85% of ER-positive tumors were CD71-positive with a monomorphic type of reaction; p=0.014. Among ER-negative tumors, CD71-negative reactions were 2-fold more frequent and the monomorphic type was less frequent. ER-positive tumors were CD29-positive in 73%; p=0.031. 45.5% of ER+ tumors were CD29-monomorphic. Among ER-negative tumors, the frequency of CD29-monomorphic tumors was 55%. Significant infiltration by CD3+ cells was predominant in CD71-positive tumors; p=0.016. In the CD29-monomorphic phenotype, CD45+ infiltration was 31.3%, and in the mosaic phenotype, 67.1%.

CONCLUSION

BC aberrantly expresses transferrin receptors, β1-integrins. CD71 expression is associated with ER expression. ER-positive tumors are often monomorphic for CD71. Prominent CD3+ infiltration was present in CD71+ tumors. Expression of β1-integrins correlated with ER+ status and weak immune infiltration.

Keywords:

breast cancer
immunofluorescence
transferrin receptors CD71
β-1 integrins
immune infiltration

Authors:

Chulkova S.V.

N.N. Blokhin National Medical Research Center of Oncology;
Pirogov Russian National Research Medical University

Sholokhova E.N.

N.N. Blokhin National Medical Research Center of Oncology

Poddubnaya I.V.

Russian Medical Academy of Continuous Professional Education

Gladilina I.A.

N.N. Blokhin National Medical Research Center of Oncology;
Pirogov Russian National Research Medical University

Egorova A.V.

Pirogov Russian National Research Medical University

Stilidi I.S.

N.N. Blokhin National Medical Research Center of Oncology;
Pirogov Russian National Research Medical University

Received:

25.01.2024

Accepted:

24.04.2024

List of references:

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.  https://doi.org/10.3322/caac.21660
  2. McCormack V, McKenzie F, Foerster M, Zietsman A, Galukande M, Adisa C, Anele A, Parham G, Pinder LF, Cubasch H, et al. Breast cancer survival and survival gap apportionment in sub-Saharan Africa (ABC-DO): a prospective cohort study. Lancet Glob Health. 2020;8(9):e1203-e1212. https://doi.org/10.1016/S2214-109X(20)30261-8
  3. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.  https://doi.org/10.1038/35021093
  4. Mutebi M, Anderson BO, Duggan C, Adebamowo C, Agarwal G, Ali Z, Bird P, Bourque JM, DeBoer R, Gebrim LH, et al. Breast cancer treatment: a phased approach to implementation. Cancer. 2020;126(suppl 10):2365-2378. https://doi.org/10.1002/cncr.32910
  5. Titov KS, Kazakov AM, Baryshnikova MA, Ryabchikov DA, Chulkova SV, Zar’yanov DA. Nekotorye molekulyarnye i immunologicheskie faktory prognoza trizhdy negativnogo raka molochnoi zhelezy. Onkoginekologiya. 2019;(4):26-34. (In Russ.). https://doi.org/10.52313/22278710_2019_4_26
  6. Ryabchikov DA, Abdullaeva EI, Dudina IA, Chulkova SV, Denchik DA, Chkhikvadze NV, Talipov OA, Vorotnikov IK. Rol’ mikro-RNK v kantserogeneze i prognoze zlokachestvennykh novoobrazovanii molochnoi zhelezy. Vestnik Rossiiskogo Nauchnogo Tsentra Rentgenoradiologii Minzdrava Rossii. 2018;18(2):5. (In Russ.).
  7. Chulkova SV, Markina IG, Antipova AS, Grishchenko NV, Pustynskii IV, Egorova AV, Ryabchikov DA, Sinel’nikov IE. Rol’ stvolovykh kletok v kantserogeneze i prognoze melanomy. Vestnik Rossiiskogo Nauchnogo Tsentra Rentgenoradiologii Minzdrava Rossii. 2018;18(4):100-116. (In Russ.). https://www.elibrary.ru/item.asp?id=37074111
  8. Kawabata H. Transferrin and transferrin receptors update. Free Radic Biol Med. 2019;133:46-54.  https://doi.org/10.1016/j.freeradbiomed.2018.06.037
  9. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell. 2010;142(1):24-38.  https://doi.org/10.1016/j.cell.2010.06.028
  10. Wang Y, Yu L, Ding J, Chen Y. Iron metabolism in cancer. Int J Mol Sci. 2018;20(1):95.  https://doi.org/10.3390/ijms20010095
  11. Marques O, Porto G, Rêma A, Faria F, Cruz Paula A, Gomez-Lazaro M, Silva P, Martins da Silva B, Lopes C. Local iron homeostasis in the breast ductal carcinoma microenvironment. BMC Cancer. 2016;16:187.  https://doi.org/10.1186/s12885-016-2228-y
  12. Greene CJ, Attwood K, Sharma NJ, Gross KW, Smith GJ, Xu B, Kauffman EC. Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients. Oncotarget. 2017;8(63):107052-107075. https://doi.org/10.18632/oncotarget.22323
  13. Jamnongkan W, Thanan R, Techasen A, Namwat N, Loilome W, Intarawichian P, Titapun A, Yongvanit P. Upregulation of transferrin receptor-1 induces cholangiocarcinoma progression via induction of labile iron pool. Tumour Biol. 2017;39(7):1010428317717655. https://doi.org/10.1177/1010428317717655
  14. Chan KT, Choi MY, Lai KK, Tan W, Tung LN, Lam HY, Tong DK, Lee NP, Law S. Overexpression of transferrin receptor CD71 and its tumorigenic properties in esophageal squamous cell carcinoma. Oncol Rep. 2014;31(3):1296-1304. https://doi.org/10.3892/or.2014.2981
  15. Shen Y, Li X, Dong D, Zhang B, Xue Y, Shang P. Transferrin receptor 1 in cancer: a new sight for cancer therapy. Am J Cancer Res. 2018;8(6):916-931. 
  16. Ohkuma M, Haraguchi N, Ishii H, Mimori K, Tanaka F, Kim HM, Shimomura M, Hirose H, Yanaga K, Mori M. Absence of CD71 transferrin receptor characterizes human gastric adenosquamous carcinoma stem cells. Ann Surg Oncol. 2012;19(4):1357-1364. https://doi.org/10.1245/s10434-011-1739-7
  17. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol. 2006;121(2):144-158.  https://doi.org/10.1016/j.clim.2006.06.010
  18. Artamonova EV. Rol’ immunofenotipirovaniya v diagnostike i prognoze raka molochnoi zhelezy. Immunologiya Gemopoeza. 2009; 6(1):8-51. (In Russ.).
  19. Smeland HY, Askeland C, Wik E, Knutsvik G, Molven A, Edelmann RJ, Reed RK, Warren DJ, Gullberg D, Stuhr L, et al. Integrin α11β1 is expressed in breast cancer stroma and associates with aggressive tumor phenotypes. J Pathol Clin Res. 2020;6(1):69-82.  https://doi.org/10.1002/cjp2.148
  20. Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R. β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 2011;13(4):R84.  https://doi.org/10.1186/bcr2936
  21. Dötzer K, Schlüter F, Koch FEV, Brambs CE, Anthuber S, Frangini S, Czogalla B, Burges A, Werner J, Mahner S, et al. Integrin α2β1 represents a prognostic and predictive biomarker in primary ovarian cancer. Biomedicines. 2021;9(3):289.  https://doi.org/10.3390/biomedicines9030289
  22. Acerbi I, Cassereau L, Dean I, Shi Q, Au A, Park C, Chen YY, Liphardt J, Hwang ES, Weaver VM. Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr Biol (Camb). 2015;7(10):1120-1134. https://doi.org/10.1039/c5ib00040h
  23. Bui T, Rennhack J, Mok S, Ling C, Perez M, Roccamo J, Andrechek ER, Moraes C, Muller WJ. Functional redundancy between β1 and β3 integrin in activating the IR/Akt/mTORC1 signaling axis to promote ErbB2-driven breast cancer. Cell Rep. 2019;29(3):589-602.e6.  https://doi.org/10.1016/j.celrep.2019.09.004
  24. Krakhmal’ NV, Telegina NS, Zav’yalova MV, Vtorushin SV, Krokhmal’ VA, Perel’muter VM. Svyaz’ osobennostei ekspressii integrinov β1 i β3 s limfogennym metastazirovaniem pri invazivnoi kartsinome nespetsificheskogo tipa molochnoi zhelezy s uchetom morfologicheskoi geterogennosti opukholi. Sibirskii Zhurnal Klinicheskoi i Eksperimental’noi Meditsiny. 2021;36(4):78-85. (In Russ.). https://doi.org/10.29001/2073-8552-2021-36-4-78-85
  25. Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR, Aleskandarany M, Paish EC, Douglas Macmillan R, Nicholson RI, et al. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res Treat. 2010;119(2):283293. https://doi.org/10.1007/s10549-009-0345-x
  26. Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, et al. Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2+ breast cancer. Cancer Res. 2017;77(12):3280-3292. https://doi.org/10.1158/0008-5472.CAN-16-2808
  27. Zhang L, Qu J, Qi Y, Duan Y, Huang YW, Zhou Z, Li P, Yao J, Huang B, Zhang S, et al. EZH2 engages TGFβ signaling to promote breast cancer bone metastasis via integrin β1-FAK activation. Nat Commun. 2022;13(1):2543. https://doi.org/10.1038/s41467-022-30105-0
  28. Baltes F, Pfeifer V, Silbermann K, Caspers J, Wantoch von Rekowski K, Schlesinger M, Bendas G. β1-Integrin binding to collagen type 1 transmits breast cancer cells into chemoresistance by activating ABC efflux transporters. Biochim Biophys Acta Mol Cell Res. 2020;1867(5):118663. https://doi.org/10.1016/j.bbamcr.2020.118663

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.